Data-Driven Risk Assessment Enables Smart Decisions On Development Strategy

As the number of new molecular entities coming out of discovery exhibit developability challenges, developers are looking for ways to predict and overcome potential issues.  During preclinical research, important distinctive tools are those capable of improving early-phase decisions.  Catalent can help select the best form among several promising candidates with our expertise in solid state chemistry, human drug metabolism & pharmacokinetic (DMPK) predictability, and formulation technology to enhance bioavailability

Click Here to Download Brochure